Stifel analyst Jonathan Block lowered the firm’s price target on Beta Bionics (BBNX) to $22 from $25 and keeps a Buy rating on the shares. Q4 results included “few surprises,” says the analyst, who sees an “upward bias” to initial 2026 guidance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds
- Beta Bionics sees FY26 revenue $130M-$135M, consensus $132.68M
- Beta Bionics reports Q4 EPS (30c), consensus (38c)
- Is BBNX a Buy, Before Earnings?
- Oracle gets upgrade and downgrade: Wall Street’s top analyst calls